HRMY

Peers: JAZZ AXSM ALKS ACAD APMD SUPN NBIX TAK INDV ANIP

| Held by: IJR AVUV VTI VB IWM FESM VBK DFAT VXF DFSV

Index	RUT
Market Cap	1.98B
Enterprise Value	1.44B
Income	178.60M
Sales	989.36M
Book/sh	18.26
Cash/sh	13.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	293
IPO	Aug 19, 2020

P/E	11.12
Forward P/E	8.30
PEG	0.45
P/S	2.00
P/B	1.84
P/C	2.56
P/FCF	6.12
EV/EBITDA	5.88
EV/Sales	1.45
Quick Ratio	3.42
Current Ratio	3.44
Debt/Eq	0.22
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	3.03
EPS next Y	4.06
EPS next Q	1.03
EPS this Y	35.16%
EPS next Y	10.73%
EPS next 5Y	18.28%
EPS past 3/5Y	-3.00% -
Sales past 3/5Y	25.64% 40.30%
EPS Y/Y TTM	-4.89%
Sales Y/Y TTM	19.79%
EPS Q/Q	-6.78%
Sales Q/Q	12.30%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	-25.53% -1.15%

Insider Own	13.80%
Insider Trans	-0.89%
Inst Own	99.32%
Inst Trans	-0.51%
ROA	13.30%
ROE	18.73%
ROIC	14.81%
Gross Margin	71.62%
Oper. Margin	22.17%
Profit Margin	18.05%
SMA20	-8.58%
SMA50	-14.20%
SMA200	-2.79%
Trades

Shs Outstand	58.72M
Shs Float	50.62M
Short Float	10.69%
Short Ratio	5.55
Short Interest	5.41M
52W High	43.49 -22.57%
52W Low	25.90 30.00%
Volatility	6.89% 5.06%
ATR (14)	1.77
RSI (14)	34.21
Beta	1.01
Rel Volume	0.55
Avg Volume	975.94K
Volume	247,813

Perf Week	-11.17%
Perf Month	-16.40%
Perf Quarter	-14.79%
Perf Half Y	11.58%
Perf YTD	-10.01%
Perf Year	7.14%
Perf 3Y	44.46%
Perf 5Y	-20.17%
Perf 10Y	-
Recom	1.75
Target Price	48.08
Prev Close	33.11
Price	33.67
Change %	1.70%

Consensus

Buy

Avg. Price Target

$48.08

Implied Upside

+42.8%

Analysts14incl. previous ratings

Rating Distribution9 Buy · 4 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	LLadenburg Thalmann	Buy	$55	+63.3%
Aug 26, 2026	Initiated	WWolfe Research	Outperform	$60	+78.2%
Feb 23, 2026	Downgrade	TTruist	Buy → Hold
Feb 23, 2026	Downgrade	DDeutsche Bank	Buy → Hold
Feb 11, 2026	Resumed	UUBS	Neutral	$46	+36.6%
Jul 21, 2025	Initiated	TTruist	Buy	$48	+42.5%
Jul 10, 2025	Resumed	GGoldman	Neutral	$33	-2.0%
Jun 02, 2025	Resumed	OOppenheimer	Outperform	$61	+81.2%
Feb 11, 2025	Initiated	DDeutsche Bank	Buy	$55	+63.3%
Dec 17, 2024	Initiated	HH.C. Wainwright	Buy	$75	+122.7%
Oct 10, 2024	Resumed	RRaymond James	Outperform
Sep 10, 2024	Initiated	UUBS	Buy	$56	+66.3%
Jun 21, 2024	Initiated	CCitigroup	Buy	$48	+42.5%
Jan 02, 2024	Downgrade	BBofA Securities	Neutral → Underperform	$30	-10.9%
Sep 25, 2023	Downgrade	GGoldman	Neutral → Sell	$40 → $31	-7.9%
Sep 07, 2023	Initiated	BBerenberg	Buy	$59	+75.2%
Apr 20, 2023	Initiated	BBofA Securities	Neutral	$35	+3.9%
Oct 14, 2022	Upgrade	JJefferies	Hold → Buy	$57 → $61	+81.2%
Oct 14, 2022	Upgrade	JJanney	Neutral → Buy	$57 → $61	+81.2%
Aug 03, 2022	Downgrade	JJefferies	Buy → Hold	$57	+69.3%

Nov-04-26 01:25PM	Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming (Earnings Whispers) -7.04%
07:30AM	Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile (GlobeNewswire)
Oct-27-26 01:18PM	Harmony Biosciences Must Prove WAKIX Momentum Can Carry Street To Top Of Guidance (Earnings Whispers)
Oct-22-26 12:19AM	Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences (Barrons.com) -5.95%
Oct-20-26 08:05AM	Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
10:15AM	Loading…
Oct-12-26 10:15AM	Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit (Investor's Business Daily) -5.09%
07:00AM	Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth (GlobeNewswire)
Oct-01-26 08:05AM	Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days (GlobeNewswire)
Sep-03-26 08:05AM	Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress (GlobeNewswire)
Aug-27-26 08:05AM	Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-26-26 09:41AM	Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-26 08:05AM	Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium (GlobeNewswire)
Aug-04-26 05:02PM	Harmony Biosciences Holdings Inc (HRMY) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com) +8.93%
07:30AM	Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile (GlobeNewswire)
Aug-03-26 09:24AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Q2 2026 -- GF Value Sees 57% Upside (GuruFocus.com)
08:05AM	Loading…
Jul-21-26 08:05AM	Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 (GlobeNewswire) +9.97%
Jul-16-26 10:37AM	Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition Says Executives Departure Not Due To Any Disagreement (Stocktwits)
08:30AM	Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition (Business Wire)
Jun-11-26 08:05AM	Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting (Business Wire)
Jun-04-26 01:14AM	Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. (Barrons.com)
May-27-26 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
May-07-26 07:30AM	Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities (Business Wire)
May-06-26 09:25AM	Harmony Biosciences Holdings Inc (HRMY) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-23-26 08:05AM	Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-16-26 08:05AM	Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting (Business Wire)
Apr-14-26 08:05AM	Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer (Business Wire)
Apr-02-26 08:05AM	Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board (Business Wire)
Mar-31-26 08:05AM	Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-04-26 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Mar-01-26 04:27AM	Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31 (Insider Monkey)
08:57AM	Loading…
Feb-26-26 08:57AM	Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments (Insider Monkey)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 04:02PM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
11:47AM	Harmony Biosciences Q4 Earnings Call Highlights (MarketBeat)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion (Business Wire)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks) -7.85%
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
07:23AM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -15.21%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
04:07AM	Zacks.com featured highlights include Harmony Biosciences, Tripadvisor, The AES and Concentrix (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
10:45AM	4 Value Stocks to Buy Now Amid AI-Driven Market Volatility (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
07:14AM	Top 5 Bargain P/B Stocks Investors Should Watch Now (Zacks)
Feb-17-26 10:00AM	Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline (Zacks)
08:05AM	Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy (Business Wire)
Feb-16-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY) (Zacks)
Feb-12-26 09:55AM	Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade (Zacks)
Feb-11-26 11:40AM	HRMY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? (Zacks)
Feb-10-26 08:05AM	Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
10:22AM	Zacks.com featured highlights include Harmony Biosciences, Adecoagro, Sociedad Quimica y Minera de Chile, Angi and PHINIA (Zacks)
Feb-04-26 09:39AM	5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions (Zacks)
Feb-02-26 07:20AM	5 Low Price-to-Book Stocks That Are Worth Watching in February (Zacks)
06:14AM	Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments (Zacks)
Jan-30-26 11:30AM	4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street (Zacks)
Jan-29-26 03:00PM	4 GARP Stocks With Attractive PEG Ratios and Strong Growth Outlooks (Zacks)
12:45PM	Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Jan-28-26 12:24PM	How Harmony Biosciences Can Prove Its Skeptics Wrong (Motley Fool)
12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 12:21PM	I Was Shocked to Find This Value-Priced Biotech Growth Stock (Motley Fool)
11:40AM	HRMY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Should Value Investors Buy Harmony Biosciences (HRMY) Stock? (Zacks)
Jan-15-26 08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-13-26 12:45PM	Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why (Zacks) -6.56%
Jan-12-26 08:05AM	Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation (Business Wire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? (Zacks)
Jan-07-26 08:05AM	Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-08-25 08:05AM	Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome (Business Wire)
Dec-02-25 08:05AM	Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-24-25 08:05AM	Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation (Business Wire)
Nov-19-25 08:05AM	Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence (Business Wire)
Nov-18-25 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 08:01AM	Harmony Biosciences Holdings Inc (HRMY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M (Business Wire)
Nov-03-25 07:38AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q3 2025 Result (GuruFocus.com)
Oct-31-25 10:29PM	Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY) (Insider Monkey)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-23-25 08:05AM	Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance (Business Wire) +12.68%
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Sep-29-25 06:54PM	H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 18 '26	Option Exercise	30.39	35,852	1,089,611	48,967	Sep 18 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 16 '26	Option Exercise	30.48	1,800	54,864	14,915	Sep 18 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 17 '26	Option Exercise	30.48	800	24,384	13,915	Sep 18 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 18 '26	Sale	43.05	35,852	1,543,590	13,115	Sep 18 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 16 '26	Sale	43.01	1,800	77,426	13,115	Sep 18 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 17 '26	Sale	43.00	800	34,400	13,115	Sep 18 04:48 PM
KUMAR BUDUR	Officer	Sep 18 '26	Proposed Sale	42.74	35,852	1,532,314		Sep 18 04:19 PM
KUMAR BUDUR	Officer	Sep 17 '26	Proposed Sale	42.21	800	33,768		Sep 17 04:34 PM
KUMAR BUDUR	Officer	Sep 16 '26	Proposed Sale	42.17	1,800	75,906		Sep 16 04:33 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 08 '26	Option Exercise	30.49	22,954	699,942	36,069	Sep 09 05:12 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 08 '26	Sale	42.96	28,454	1,222,258	13,115	Sep 09 05:12 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Sep 04 '26	Sale	41.98	5,500	230,911	18,615	Sep 09 05:12 PM
KUMAR BUDUR	Officer	Sep 08 '26	Proposed Sale	42.25	28,454	1,202,182		Sep 08 04:29 PM
KUMAR BUDUR	Officer	Sep 04 '26	Proposed Sale	41.86	5,500	230,230		Sep 04 04:31 PM
VALOR IV PHARMA HOLDINGS LLC	Director	Aug 07 '26	Proposed Sale	37.90	700,883	26,563,466		Aug 07 04:48 PM
SANDIP KAPADIA	Former Officer	Jul 02 '26	Proposed Sale	36.96	25,000	924,008		Jul 02 04:06 PM
SANDIP KAPADIA	Former Officer	Jun 30 '26	Proposed Sale	36.08	50,000	1,803,825		Jun 30 04:04 PM
SANDIP KAPADIA	Former Officer	Jun 26 '26	Proposed Sale	35.24	45,594	1,606,824		Jun 26 04:17 PM
SANDIP KAPADIA	Former Officer	Jun 24 '26	Proposed Sale	35.02	4,406	154,302		Jun 24 04:18 PM
SANDIP KAPADIA	Former Officer	Jun 09 '26	Proposed Sale	33.74	27,960	943,264		Jun 09 04:28 PM
SANDIP KAPADIA	Former Officer	Jun 05 '26	Proposed Sale	33.08	2,101	69,504		Jun 05 04:13 PM
SANDIP KAPADIA	Former Officer	Jun 04 '26	Proposed Sale	33.02	7,064	233,232		Jun 04 04:23 PM
Budur Kumar	CHIEF MEDICAL OFFICER	May 01 '26	Option Exercise	0.00	18,750	0	32,997	May 18 04:14 PM
SANDIP KAPADIA	Former Officer	May 08 '26	Proposed Sale	31.51	45,481	1,433,056		May 08 04:08 PM
Zaeske Adam H.	CHIEF COMMERCIAL OFFICER	Apr 07 '26	Option Exercise	0.00	7,500	0	7,500	Apr 09 04:15 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	37.15	3,746	139,171	24,521	Jan 28 08:19 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 25 '26	Option Exercise	0.00	4,725	0	4,725	Jan 26 04:49 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 24 '26	Option Exercise	0.00	3,813	0	3,813	Jan 26 04:49 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 25 '26	Option Exercise	0.00	2,600	0	2,600	Jan 26 04:48 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 24 '26	Option Exercise	0.00	2,500	0	2,500	Jan 26 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 25 '26	Option Exercise	0.00	2,662	0	2,662	Jan 26 04:45 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 24 '26	Option Exercise	0.00	2,188	0	2,188	Jan 26 04:45 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 25 '26	Option Exercise	0.00	13,000	0	13,000	Jan 26 04:43 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 24 '26	Option Exercise	0.00	10,500	0	10,500	Jan 26 04:43 PM
SANDIP KAPADIA	Officer	Jan 26 '26	Proposed Sale	36.82	3,746	137,928		Jan 26 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 15 '26	Sale	35.92	20,961	752,833	0	Jan 20 08:39 PM
SANDIP KAPADIA	Officer	Jan 15 '26	Proposed Sale	36.04	20,961	755,434		Jan 15 04:22 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Option Exercise	8.22	20,000	164,400	20,000	Dec 17 05:25 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Sale	40.11	25,933	1,040,103	0	Dec 17 05:25 PM
JEFFREY M DAYNO	Director	Dec 12 '25	Proposed Sale	39.59	25,933	1,026,687		Dec 12 04:25 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Option Exercise	29.03	20,000	580,600	20,000	Dec 09 04:10 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Sale	39.54	20,000	790,896	0	Dec 09 04:10 PM
SANDIP KAPADIA	Officer	Dec 05 '25	Proposed Sale	38.25	20,000	765,000		Dec 05 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Nov 21 '25	Sale	35.00	3,427	119,945	0	Nov 25 04:10 PM
SANDIP KAPADIA	Officer	Nov 21 '25	Proposed Sale	33.39	3,427	114,428		Nov 21 04:46 PM

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Founder & Non-Executive ChairmanMr. Jeffrey S. Aronin

PresidentDr. Jeffrey M. Dayno M.D.

Senior Executive VP & COOMr. Peter Anastasiou

M.S.Dr. Kumar Budur M.D.

M.B.A.Mr. Andrew Serafin J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Harmony Biosciences Holdings Inc

Upgrade your Finviz experience